| 22 Dec 2005 |
Contract Manufacturing Agreement Takes PER.C6® into Canada |
| 22 Dec 2005 |
Crucell Announces Second PER.C6® Licensing Agreement with Merial |
| 22 Dec 2005 |
Crucell and WRAIR Sign CRADA to Evaluate PER.C6® Technology for Development of Flavivirus Vaccines |
| 21 Dec 2005 |
Crucell and DSM Announce Second PER.C6® License Agreement with Ferring Pharmaceuticals |
| 21 Dec 2005 |
Crucell and DSM Announce PER.C6® Licensing Agreement with ZyStor Therapeutics |
| 20 Dec 2005 |
Crucell and DSM further strengthen and expand the development of PER.C6® Protein and Monoclonal Antibody Licensing Business |
| 19 Dec 2005 |
Crucell Notes Berna Announcement of Due Diligence Request |
| 19 Dec 2005 |
Crucell Announces STAR(TM) Licensing Agreement with Genzyme |
| 16 Dec 2005 |
Crucell Gains Approval and Moves to Recruitment for West Nile Vaccine Phase I Clinical Study |
| 08 Dec 2005 |
Crucell Announces PER.C6® Licensing Agreement with Vakzine Projekt Management |
| 23 Nov 2005 |
Crucell Announces PER.C6® Licensing Agreement with Tibotec |
| 02 Nov 2005 |
Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program |
| 01 Nov 2005 |
Crucell to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference, November 8 |
| 20 Oct 2005 |
Tokyo Infectious Diseases Forum Highlights Strategies to Combat Flu and Other Pandemics |
| 19 Oct 2005 |
Crucell and DSM Announce PER.C6® Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax |
| 17 Oct 2005 |
Crucell Announces Third Quarter 2005 Results |
| 13 Oct 2005 |
Crucell Updates Progress in Scale-up of Cell-culture-based Influenza Vaccine Programs |
| 10 Oct 2005 |
Merck and Co., Inc. Exercises Option on PER.C6® License for Adenovirus-based Vaccine Against Hepatitis C |
| 03 Oct 2005 |
Crucell to Release Third Quarter Results on Monday, October 17 |
| 30 Sep 2005 |
Crucell Files Financial Statements with Euronext for H1 2005 in Accordance with IFRS |
| 27 Sep 2005 |
Crucell Clarifies CFO Comment Made at UBS Conference |
| 21 Sep 2005 |
Crucell to Present at UBS Global Life Sciences Conference, New York, September 26 |
| 20 Sep 2005 |
Crucell Appoints Agents to Boost Asian Market Potential |
| 16 Sep 2005 |
Crucell Secures € 2 Million Grant from Dutch Ministry of Economic Affairs to Discover Antibodies Against Antibiotic-resistant Bacterial Infections |
| 08 Sep 2005 |
Crucell and Aeras Announce Progress in TB Vaccine Program |
| 17 Aug 2005 |
Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague |
| 16 Aug 2005 |
Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron |
| 01 Aug 2005 |
Harvard and Crucell Receive $19.2 million NIH Grant to Develop Next-Generation AdVac®-based Vaccines |
| 18 Jul 2005 |
Crucell Announces Second Quarter 2005 Results |
| 15 Jul 2005 |
Crucell and DSM Announce PER.C6® Licensing Agreement with Symphogen for Polyclonal Antibody Protein Production |
| 14 Jul 2005 |
Crucell Announces Clinical Development of Human Monoclonal Antibody Combination Against Rabies |
| 13 Jul 2005 |
Crucell NV Options to be Listed on Euronext.liffe Amsterdam |
| 05 Jul 2005 |
Crucell to Release Second Quarter Results on Monday, July 18 |
| 28 Jun 2005 |
Fidelity Fund Acquires 5.13% Interest in Crucell |
| 10 Jun 2005 |
Human Monoclonal Antibody Against West Nile Virus Shows Promise in Animal Studies |
| 01 Jun 2005 |
Crucell announces STAR(TM) arrangement with Medarex |
| 31 May 2005 |
Crucell NV Options Listed on Chicago Board Options Exchange |
| 25 May 2005 |
Crucell and DSM Announce PER.C6® License Agreement with Ferring Pharmaceuticals |
| 20 May 2005 |
Crucell to Present at Needham & Company Fourth Annual Biotechnology Conference, May 26 |
| 10 May 2005 |
Crucell Equity Offering Priced at € 14.50 per Share; € 52.2 Million Raised |
| 29 Apr 2005 |
Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies |
| 27 Apr 2005 |
Crucell to Present at Rodman & Renshaw 2nd Annual Global Healthcare Conference, May 4 |
| 18 Apr 2005 |
Crucell Announces First Quarter 2005 Results |
| 14 Apr 2005 |
Crucell and NIH sign € 21.4 million Ebola Vaccine Manufacturing Contract |
| 05 Apr 2005 |
Crucell to Release First Quarter 2005 Earnings on Monday, April 18 |
| 05 Apr 2005 |
Crucell Receives US Patent Covering its STAR(TM) Technology |
| 01 Apr 2005 |
Crucell's Cell-Culture Technology to Be Part of Major U.S. Government Influenza Pandemic Vaccine Program |
| 01 Apr 2005 |
AFM Completes Investigation into Exercising of Options by Crucell Management |
| 30 Mar 2005 |
Crucell Announces PER.C6® Licensing Agreement with Vascular Biogenics |
| 23 Mar 2005 |
Crucell and DSM Announce PER.C6® Licensing Agreement with Mitsubishi Pharma for Protein Production |
| 22 Mar 2005 |
Crucell Signs Commercial PER.C6® License Agreement with SingVax for Vaccines against Japanese Encephalitis |
| 18 Mar 2005 |
Crucell Secures Exclusive Patent License from NIH to Commercialize Ebola Vaccines |
| 17 Mar 2005 |
Crucell and NIH extend Ebola Vaccine Agreement |
| 10 Mar 2005 |
Crucell and DSM Announce PER.C6® Licensing Agreement with JCR Pharmaceuticals for Protein Production |
| 09 Mar 2005 |
Galapagos is considering a stock exchange listing |
| 16 Feb 2005 |
Crucell and DSM Announce PER.C6® Licensing and Service Agreement with Roche for Protein Production |
| 16 Feb 2005 |
Crucell Receives Patents Covering PER.C6® for Protein Production |
| 31 Jan 2005 |
Crucell Confirms Selection for Amsterdam Midkap Index on Euronext |
| 26 Jan 2005 |
Crucell Fully Compliant |
| 24 Jan 2005 |
Crucell Announces 2004 Annual Results |
| 14 Jan 2005 |
Crucell Joins Influenza Vaccine Supply (IVS) International Task Force |
| 10 Jan 2005 |
Crucell to Release 2004 Earnings on Monday, January 24, 2005 |
| 07 Jan 2005 |
Crucell Announces Evaluation by Genentech of STAR(TM) Technology |
| 05 Jan 2005 |
Crucell Receives European Patent Covering PER.C6® for Vaccine Production |
